A new report from financial services company The Heligan Group reveals healthcare remains one of the UK’s most resilient M&A sectors despite continued economic uncertainty.
UK healthcare recorded 78 announced and completed M&A deals in Q2 2026, up from 53 in Q1 2026. This is according to Heligan Group’s latest Q2 UK Healthcare M&A Update, which found that Health and Social Care accounted for 69% of transactions.
After a cautious start to the year, deal activity remained broadly in line with Q2 2025, with domestic buyers continuing to dominate the market. Strategic acquirers accounted for 86% of all deals completed during the quarter, highlighting continued confidence in healthcare despite macroeconomic uncertainty.
“While broader deal making remains challenging with geopolitical uncertainty and domestic political pressures, the healthcare sector continues to demonstrate resilience,” said Ramesh Jassal, Partner, Healthcare at Heligan Group. “Long-term demand drivers are still giving buyers clear reasons to invest, even where diligence is taking longer, and valuations are being tested.
“Meanwhile, internal UK transactions accounted for 69% of all activity compared with 22% of outbound activity. The market remains largely UK-led, with overseas expansion taking place only where there is clear strategic rationale.”
The report found that Pharmaceuticals and Life Sciences generated the quarter’s highest-value transactions, led by GSK’s proposed £7.95bn acquisition of Nuvalent and its earlier agreement to acquire Siran Biotechnology for up to £750m. These transactions highlight continued demand for differentiated, late-stage life sciences assets.
“The GSK acquisition underlines the company’s strategy of acquiring late-stage, differentiated oncology assets with near-term commercial potential. This reflects a continued appetite among major pharmaceutical companies for differentiated assets capable of strengthening long-term growth pipelines.”
The highest level of activity was seen within Health and Social Care, spanning residential elderly care, specialist care, childcare and nurseries, and home care. The report also identified nursery and childcare as one of the busiest specialist markets, with operators continuing to consolidate a highly fragmented market through the acquisition of smaller providers.
“Health and Social Care was the most active segment, accounting for 69% of all healthcare transactions and reflecting the breadth of consolidation pressures across the care economy. Within this, the nursery market was one of the most active subsectors in UK healthcare M&A during Q2 2026.”
“Nursery transactions accounted for 14% of deals across the quarter. The market remains fragmented, with many independent settings facing rising staffing costs, tighter regulatory demands and increasing administrative complexity around funded childcare hours.”
Jassal continued: “For larger operators, this creates a compelling consolidation opportunity: acquire smaller nurseries, professionalise operations, improve utilisation and benefit from procurement, systems and management efficiencies. This helps build scale in fragmented markets.”
Looking ahead, Jassal expects consolidation activity to continue across healthcare subsectors, supported by strong underlying demand, demographic trends and ongoing strategic buyer interest.
“Healthcare remains one of the most resilient areas of the UK M&A market. We expect consolidation activity to continue across care services, healthcare technology, specialist providers and life sciences, while nursery M&A is also likely to remain active given the sector’s fragmented ownership structure and favourable long-term demand drivers.”
